NASDAQ:SYN - Synthetic Biologics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.35 +0.31 (+15.20 %)
(As of 09/21/2018 06:02 AM ET)
Previous Close$2.04
Today's Range$1.95 - $2.43
52-Week Range$1.86 - $36.75
Volume296,100 shs
Average Volume43,505 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYN
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares3,800,000
Market Cap$0.00

Synthetic Biologics (NASDAQ:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the NASDAQ under the ticker symbol "SYN."

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc (NASDAQ:SYN) issued its earnings results on Wednesday, August, 8th. The company reported ($1.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.40) by $0.35. View Synthetic Biologics' Earnings History.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Synthetic Biologics.

What is the consensus analysts' recommendation for Synthetic Biologics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthetic Biologics.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:
  • Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
  • Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

Has Synthetic Biologics been receiving favorable news coverage?

Media headlines about SYN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Synthetic Biologics earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Synthetic Biologics.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $2.35.


MarketBeat Community Rating for Synthetic Biologics (NASDAQ SYN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel